Doctolib

Active#5 in France

Appointment booking and practice software

Healthtech›appointment booking and practice software

Founded2013

HQParis

RaisedUSD ~840M (EUR ~770M)

Last roundSecondary share sale · Apr 2026

Country of originFranceListed in the France ranking

Where would you invest?HQ Paris; operations in France, Germany, Italy and the NetherlandsJurisdiction as cited by the ranking

Uback rankings

How the AI ranks →

Ranking	Tier	Rank	Edition	Next update
France · all sectors	Top 25	#5	Edition 0 – beta · September 2026	19 Oct 2026
Appointment booking · worldwide	Top 9	#1	Edition 0 (beta) · Sep 2026	18 Jan 2027

Rank historySep 2026 · #1 Appointment bookingSep 2026 · #5 FranceFirst edition: no movements yet.

Estimated valuation

AI · France ranking

≈ USD 4.1bnUSD 3.3–5.1bn · Unicorn High confidence

Hundreds of k$

Millions $

Tens of M$

Hundreds of M$

Unicorn

Decacorn

Anchor: Last known equity round: Late-stage round (equity and debt) · USD 549M · Mar 2022
Published valuation: USD 4.1bn · Apr 2026
AI adjustment: None

In the Appointment booking ranking (worldwide): ≈ USD 4.3bn · USD 3.4–5.4bn · Unicorn · High confidence.

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Funding history

USD ~840M (EUR ~770M) raised in total

Date	Round	Amount	Type	Investors	Source
Apr 2026	Secondary share sale	USD ~345M (EUR ~300M)	—	Generation IM	maddyness.com
Mar 2022	Series F	EUR 500M	Equity	General Atlantic	bloomberg.com

Rounds as cited by Uback’s rankings and their sources. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of Doctolib as a PDF, on one of three angles only:

ValuationWhat is Doctolib worth?

Versus competitorsIs #5 the right rank?

Who should acquire itStrategic buyers, and why

Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication and never change the rank.

Invest

Doctolib is not open to Backers. A company opens only when a shareholder plans to sell or the company plans to raise.

Back the market instead: your intention joins a pool, passed to the local partner once it reaches critical mass.

Declare an interest in French startups Declare an interest in French healthtech Name Doctolib as a preferred company (measures demand, promises nothing)

France poolBelow threshold

BackersBelow threshold

Paid intention · valid for life · movable until its pool is passed on. Investing in non-listed companies carries a risk of losing all the capital invested.

Do you run Doctolib?

Claim this profile to correct data, add your logo and description, or tell Uback about an upcoming round. Claiming never changes the rank.

Claim this profile Report an upcoming round →

Are you a shareholder?

Considering selling some of your shares? Tell Uback privately. Nothing is published without your consent, and never a price or a volume.

Tell Uback privately

What the AI reads

Press & investor announcements4 sources

Pappers (French company registry)Planned

Read by the AI at the next edition.

Comparable companies in France

Full France ranking →

DentalMonitoring#20Healthtech › AI remote orthodontic monitoringUnicorn Pennylane#4Fintech › SME accounting and finance softwareUnicorn Brevo#6Business software › CRM and marketing automationUnicorn AMI Labs#3AI › world modelsUnicorn

Investors in Doctolib: Generation Investment Management · General Atlantic

Sources. maddyness.com · bloomberg.com · inforcapital.com · forbes.com

Last updated: Sep 2026Report an error

Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.